[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-apitegromab-isembyld-glp1-muscle-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":1390,"_id":1391,"_source":1392,"_file":1393,"_stem":1394,"_extension":1395},"\u002Fblog\u002Fzh\u002Fapitegromab-isembyld-glp1-muscle","zh",false,"","Apitegromab 以 ISEMBYLD 之名获批——而大家真正关心的「GLP-1 掉肌肉」仍然没有答案","下面是一般性的科普内容，不是医疗建议，也不是鼓励你去弄点什么来用。Apitegromab 是美国已获批的处方药，商品名 ISEMBYLD，由医护人员静脉输注给药。本文任何地方都不给用量，已获批的适应症也不给。文章大部分篇幅讨论的那个用法——减重期间保住去脂体重——在全球任何地方都没有获批，也没有任何地方提交过申请。","研究","tabler:file-certificate","#7A5EA6","2026-09-21","2026年9月","13 分钟","myPeptides Team","\u002Fassets\u002Fapitegromab_hero.png",{"type":19,"children":20,"toc":1373},"root",[21,28,48,70,77,89,178,197,203,230,317,322,334,340,359,459,471,477,482,651,656,662,674,683,688,786,796,801,813,826,831,848,858,868,874,898,903,908,920,926,1022,1034,1040,1067,1079,1085,1090,1118,1123,1128,1133,1138,1143],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":23,"props":29,"children":30},{},[31,33,39,41,46],{"type":27,"value":32},"2026 年 9 月 11 日，美国食品药品监督管理局（FDA）批准了 Scholar Rock 的 ",{"type":22,"tag":34,"props":35,"children":36},"strong",{},[37],{"type":27,"value":38},"apitegromab",{"type":27,"value":40},"（商品名 ",{"type":22,"tag":34,"props":42,"children":43},{},[44],{"type":27,"value":45},"ISEMBYLD",{"type":27,"value":47},"）用于脊髓性肌萎缩症。这是全球第一款靠阻断肌抑素（myostatin，身体自带的那道肌肉生长刹车）而获批的药——不分国家，也不分适应症；在此之前的二十年里，这一类药物每一次尝试都以失败收场。它的诀窍在靶点：它结合的不是成熟的肌抑素分子，而是它尚未激活的前体，于是拿到了早年那些尝试所缺的选择性。",{"type":22,"tag":23,"props":49,"children":50},{},[51,53,60,62,68],{"type":27,"value":52},"这本身是个里程碑，但多数人读到的并不是这件事。获批的第二天，这条消息就换了一副面孔在网上流传：「保肌肉的药」，打",{"type":22,"tag":54,"props":55,"children":57},"a",{"href":56},"\u002Fglp1\u002Ftirzepatide",[58],{"type":27,"value":59},"替尔泊肽",{"type":27,"value":61},"或",{"type":22,"tag":54,"props":63,"children":65},{"href":64},"\u002Fglp1\u002Fsemaglutide",[66],{"type":27,"value":67},"司美格鲁肽",{"type":27,"value":69},"时能替你把肌肉留住的那个东西。这种说法背后确实有一项真实的试验，只是试验测到的东西和标题说的东西之间隔着一道缝。这篇文章讲的就是这道缝。",{"type":22,"tag":71,"props":72,"children":74},"h2",{"id":73},"fda-批的到底是什么",[75],{"type":27,"value":76},"FDA 批的到底是什么",{"type":22,"tag":23,"props":78,"children":79},{},[80,82,87],{"type":27,"value":81},"适应症很窄：ISEMBYLD 用于 2 岁及以上、",{"type":22,"tag":34,"props":83,"children":84},{},[85],{"type":27,"value":86},"当前正在接受 SMN2 靶向治疗",{"type":27,"value":88},"的脊髓性肌萎缩症患者，成人和儿童都包括——加在诺西那生或利司扑兰之上，而不是取而代之。在这种遗传病里，支配肌肉的神经细胞会逐渐死亡；SMN2 靶向药处理的是病因，却补不回已经失去的部分，apitegromab 补的正是这一块。",{"type":22,"tag":90,"props":91,"children":92},"table",{},[93,108],{"type":22,"tag":94,"props":95,"children":96},"thead",{},[97],{"type":22,"tag":98,"props":99,"children":100},"tr",{},[101,105],{"type":22,"tag":102,"props":103,"children":104},"th",{},[],{"type":22,"tag":102,"props":106,"children":107},{},[],{"type":22,"tag":109,"props":110,"children":111},"tbody",{},[112,126,139,152,165],{"type":22,"tag":98,"props":113,"children":114},{},[115,121],{"type":22,"tag":116,"props":117,"children":118},"td",{},[119],{"type":27,"value":120},"获批时间",{"type":22,"tag":116,"props":122,"children":123},{},[124],{"type":27,"value":125},"2026 年 9 月 11 日，FDA，BLA 761463，美国许可证号 2372",{"type":22,"tag":98,"props":127,"children":128},{},[129,134],{"type":22,"tag":116,"props":130,"children":131},{},[132],{"type":27,"value":133},"持证方",{"type":22,"tag":116,"props":135,"children":136},{},[137],{"type":27,"value":138},"Scholar Rock, Inc.，马萨诸塞州剑桥市",{"type":22,"tag":98,"props":140,"children":141},{},[142,147],{"type":22,"tag":116,"props":143,"children":144},{},[145],{"type":27,"value":146},"是什么",{"type":22,"tag":116,"props":148,"children":149},{},[150],{"type":27,"value":151},"全人源单克隆抗体，IgG4\u002Flambda，约 150 kDa（CAS 2278276-46-1）",{"type":22,"tag":98,"props":153,"children":154},{},[155,160],{"type":22,"tag":116,"props":156,"children":157},{},[158],{"type":27,"value":159},"特别资格",{"type":22,"tag":116,"props":161,"children":162},{},[163],{"type":27,"value":164},"快速通道、孤儿药、罕见儿科疾病；获批时一并拿到一张优先审评券",{"type":22,"tag":98,"props":166,"children":167},{},[168,173],{"type":22,"tag":116,"props":169,"children":170},{},[171],{"type":27,"value":172},"没有获批的用途",{"type":22,"tag":116,"props":174,"children":175},{},[176],{"type":27,"value":177},"肥胖、减重、保住肌肉——全球任何地方都没批",{"type":22,"tag":23,"props":179,"children":180},{},[181,183,188,190,195],{"type":27,"value":182},"这条路并不顺。2025 年 9 月，FDA 发过一封",{"type":22,"tag":34,"props":184,"children":185},{},[186],{"type":27,"value":187},"完整回复函（Complete Response Letter）",{"type":27,"value":189},"，等于说按当时提交的材料不予批准。Scholar Rock 当时说明，问题只出在一家第三方灌装包装厂的例行检查上，明确与疗效和安全性数据无关。欧洲目前没有这个药：欧盟申请由",{"type":22,"tag":34,"props":191,"children":192},{},[193],{"type":27,"value":194},"申请人自己在 2026 年 8 月 13 日撤回",{"type":27,"value":196},"，原因同样是生产，而不是疗效或安全性。瑞士既没有批准也没有在审申请，加拿大没有批准记录，至于日本，公司宣布会在 2026 年底之前递交申报。",{"type":22,"tag":71,"props":198,"children":200},{"id":199},"sma-那边的证据说人话",[201],{"type":27,"value":202},"SMA 那边的证据，说人话",{"type":22,"tag":23,"props":204,"children":205},{},[206,208,213,215,221,223,228],{"type":27,"value":207},"获批靠的是 ",{"type":22,"tag":34,"props":209,"children":210},{},[211],{"type":27,"value":212},"SAPPHIRE",{"type":27,"value":214},"（NCT05156320），一项三期试验，覆盖九个国家的 48 家医疗机构，2025 年发表在 ",{"type":22,"tag":216,"props":217,"children":218},"em",{},[219],{"type":27,"value":220},"The Lancet Neurology",{"type":27,"value":222},"。入组 188 人，年龄 2 到 21 岁，患 2 型或不能行走的 3 型 SMA，全部已经在用诺西那生或利司扑兰，入组时全部无法行走；128 人用 apitegromab，60 人用安慰剂，观察 52 周，主分析针对其中 2 到 12 岁的 156 名参与者。测的指标是 ",{"type":22,"tag":34,"props":224,"children":225},{},[226],{"type":27,"value":227},"Hammersmith 功能性运动量表扩展版",{"type":27,"value":229},"，由 33 个当场观察的动作组成，每个记 0、1 或 2 分：它记录的是一个人实际能做到什么——恰恰是那项肥胖试验缺的那类终点。",{"type":22,"tag":90,"props":231,"children":232},{},[233,254],{"type":22,"tag":94,"props":234,"children":235},{},[236],{"type":22,"tag":98,"props":237,"children":238},{},[239,244,249],{"type":22,"tag":102,"props":240,"children":241},{},[242],{"type":27,"value":243},"12 个月后的比较",{"type":22,"tag":102,"props":245,"children":246},{},[247],{"type":27,"value":248},"与安慰剂的差值",{"type":22,"tag":102,"props":250,"children":251},{},[252],{"type":27,"value":253},"区间与 p 值",{"type":22,"tag":109,"props":255,"children":256},{},[257,278,299],{"type":22,"tag":98,"props":258,"children":259},{},[260,265,273],{"type":22,"tag":116,"props":261,"children":262},{},[263],{"type":27,"value":264},"后来获批的那一组",{"type":22,"tag":116,"props":266,"children":267},{},[268],{"type":22,"tag":34,"props":269,"children":270},{},[271],{"type":27,"value":272},"2.2 分",{"type":22,"tag":116,"props":274,"children":275},{},[276],{"type":27,"value":277},"95% CI 0.49 到 3.95；名义 p = 0.0121",{"type":22,"tag":98,"props":279,"children":280},{},[281,286,294],{"type":22,"tag":116,"props":282,"children":283},{},[284],{"type":27,"value":285},"两组合并（预先设定的分析）",{"type":22,"tag":116,"props":287,"children":288},{},[289],{"type":22,"tag":34,"props":290,"children":291},{},[292],{"type":27,"value":293},"1.8 分",{"type":22,"tag":116,"props":295,"children":296},{},[297],{"type":27,"value":298},"95% CI 0.30 到 3.32；p = 0.019",{"type":22,"tag":98,"props":300,"children":301},{},[302,307,312],{"type":22,"tag":116,"props":303,"children":304},{},[305],{"type":27,"value":306},"试验里的另一组",{"type":22,"tag":116,"props":308,"children":309},{},[310],{"type":27,"value":311},"1.4 分",{"type":22,"tag":116,"props":313,"children":314},{},[315],{"type":27,"value":316},"95% CI −0.34 到 3.13；p = 0.11，不显著",{"type":22,"tag":23,"props":318,"children":319},{},[320],{"type":27,"value":321},"三个数字都没错，各自回答的是不同的问题；拿其中一个当另一个用，是这款药的报道里最常见的错误。换成绝对值：获批那一组涨了 1.0 分（n = 53），安慰剂组掉了 1.2 分（n = 50）。「名义」的意思是没有对同时检验多个问题做校正，说明书里 FDA 也是这么写的。",{"type":22,"tag":23,"props":323,"children":324},{},[325,327,332],{"type":27,"value":326},"说明书没有黑框警告，也没有禁忌症。但它有一条警告，而这条警告正好压在「把这类药拿来做美容用途」这种轻飘飘的说法上：",{"type":22,"tag":34,"props":328,"children":329},{},[330],{"type":27,"value":331},"骨折",{"type":27,"value":333},"。在关键试验里，后来获批那一组 53 人中有 5 人（9%）发生骨折，另一组 53 人中有 3 人（6%），安慰剂组是 1 人（2%）；开放标签延长期里有 22 人（9%）骨折，其中 5 例是严重的股骨骨折。这些人里大多数原本就骨密度低或有骨折史，动物实验也显示对骨有害。",{"type":22,"tag":71,"props":335,"children":337},{"id":336},"大家真正在问的那个问题embraze",[338],{"type":27,"value":339},"大家真正在问的那个问题：EMBRAZE",{"type":22,"tag":23,"props":341,"children":342},{},[343,345,350,352,357],{"type":27,"value":344},"GLP-1 和 GIP\u002FGLP-1 类药物能减掉不少体重，而减掉的并不全是脂肪。SURMOUNT-1 的体成分分析里，用替尔泊肽的参与者（各组合并）在 72 周里掉了 5.6 kg 去脂体重，安慰剂组是 1.2 kg，差值 −4.4 kg（95% CI −5.6 到 −3.2）；同期脂肪分别掉了 15.9 kg 和 3.6 kg。把不同试验、不同测量方法放在一起看，减掉的体重里大约 25% 到 40% 是去脂组织。问题于是自己冒出来了：如果再加上一个能松开肌肉刹车的东西，身体是不是就会少交出去一些？",{"type":22,"tag":34,"props":346,"children":347},{},[348],{"type":27,"value":349},"EMBRAZE",{"type":27,"value":351},"（NCT06445075）就是这个实验：一项二期研究，作者自己称之为概念验证，2026 年发表在 ",{"type":22,"tag":216,"props":353,"children":354},{},[355],{"type":27,"value":356},"Nature Medicine",{"type":27,"value":358},"。",{"type":22,"tag":90,"props":360,"children":361},{},[362,374],{"type":22,"tag":94,"props":363,"children":364},{},[365],{"type":22,"tag":98,"props":366,"children":367},{},[368,371],{"type":22,"tag":102,"props":369,"children":370},{},[],{"type":22,"tag":102,"props":372,"children":373},{},[],{"type":22,"tag":109,"props":375,"children":376},{},[377,390,408,421,434],{"type":22,"tag":98,"props":378,"children":379},{},[380,385],{"type":22,"tag":116,"props":381,"children":382},{},[383],{"type":27,"value":384},"设计",{"type":22,"tag":116,"props":386,"children":387},{},[388],{"type":27,"value":389},"1:1 随机、双盲、安慰剂对照、多中心、四重设盲",{"type":22,"tag":98,"props":391,"children":392},{},[393,398],{"type":22,"tag":116,"props":394,"children":395},{},[396],{"type":27,"value":397},"关键的结构",{"type":22,"tag":116,"props":399,"children":400},{},[401,406],{"type":22,"tag":34,"props":402,"children":403},{},[404],{"type":27,"value":405},"所有人",{"type":27,"value":407},"都用替尔泊肽。比的是替尔泊肽加 apitegromab 对替尔泊肽加安慰剂。没有不用替尔泊肽的那一组。",{"type":22,"tag":98,"props":409,"children":410},{},[411,416],{"type":22,"tag":116,"props":412,"children":413},{},[414],{"type":27,"value":415},"参与者",{"type":22,"tag":116,"props":417,"children":418},{},[419],{"type":27,"value":420},"随机 102 人（每组 51 人）；疗效分析纳入 apitegromab 组 43 人、安慰剂组 44 人，也就是完成试验并且在第 24 周拿到可用扫描结果的人。入组是 18 到 65 岁的成年人，肥胖，或者超重并伴有与体重相关的疾病；有心脏、血管、肺、肝、胰腺、神经肌肉或精神疾病的人，以及活动性癌症和糖尿病患者，都被排除在外。",{"type":22,"tag":98,"props":422,"children":423},{},[424,429],{"type":22,"tag":116,"props":425,"children":426},{},[427],{"type":27,"value":428},"时长",{"type":22,"tag":116,"props":430,"children":431},{},[432],{"type":27,"value":433},"治疗 24 周，随后停药 8 周到第 32 周",{"type":22,"tag":98,"props":435,"children":436},{},[437,442],{"type":22,"tag":116,"props":438,"children":439},{},[440],{"type":27,"value":441},"终点",{"type":22,"tag":116,"props":443,"children":444},{},[445,447,452,454],{"type":27,"value":446},"主要终点：第 24 周全身 DXA 扫描测得的",{"type":22,"tag":34,"props":448,"children":449},{},[450],{"type":27,"value":451},"全身去脂体重",{"type":27,"value":453},"变化，单位公斤。体能（握力、坐立测试）",{"type":22,"tag":34,"props":455,"children":456},{},[457],{"type":27,"value":458},"只是探索性终点",{"type":22,"tag":23,"props":460,"children":461},{},[462,464,469],{"type":27,"value":463},"有一个技术细节决定了下面所有数字该怎么读。这项试验采用的双侧显著性水平是 20%，因此报告的是 ",{"type":22,"tag":34,"props":465,"children":466},{},[467],{"type":27,"value":468},"80% 置信区间",{"type":27,"value":470},"，而不是通常的 95%；而且没有对多重检验做任何校正，所以所有 p 值都只是描述性的——这是作者自己说的。80% 区间比常用的 95% 窄，门槛也松：这是探索性研究的做法，不是验证性研究的做法。",{"type":22,"tag":71,"props":472,"children":474},{"id":473},"embraze-测到了什么",[475],{"type":27,"value":476},"EMBRAZE 测到了什么",{"type":22,"tag":23,"props":478,"children":479},{},[480],{"type":27,"value":481},"扫描上的差别确实有，而且不小。",{"type":22,"tag":90,"props":483,"children":484},{},[485,511],{"type":22,"tag":94,"props":486,"children":487},{},[488],{"type":22,"tag":98,"props":489,"children":490},{},[491,496,501,506],{"type":22,"tag":102,"props":492,"children":493},{},[494],{"type":27,"value":495},"第 24 周",{"type":22,"tag":102,"props":497,"children":498},{},[499],{"type":27,"value":500},"apitegromab + 替尔泊肽",{"type":22,"tag":102,"props":502,"children":503},{},[504],{"type":27,"value":505},"安慰剂 + 替尔泊肽",{"type":22,"tag":102,"props":507,"children":508},{},[509],{"type":27,"value":510},"差值",{"type":22,"tag":109,"props":512,"children":513},{},[514,554,577,600,623],{"type":22,"tag":98,"props":515,"children":516},{},[517,522,532,542],{"type":22,"tag":116,"props":518,"children":519},{},[520],{"type":27,"value":521},"去脂体重减少",{"type":22,"tag":116,"props":523,"children":524},{},[525,530],{"type":22,"tag":34,"props":526,"children":527},{},[528],{"type":27,"value":529},"1.6 kg",{"type":27,"value":531},"（80% CI 0.8 到 2.3）",{"type":22,"tag":116,"props":533,"children":534},{},[535,540],{"type":22,"tag":34,"props":536,"children":537},{},[538],{"type":27,"value":539},"3.5 kg",{"type":27,"value":541},"（2.8 到 4.1）",{"type":22,"tag":116,"props":543,"children":544},{},[545,547,552],{"type":27,"value":546},"多保住 ",{"type":22,"tag":34,"props":548,"children":549},{},[550],{"type":27,"value":551},"1.9 kg",{"type":27,"value":553},"（1.2 到 2.7；p = 0.0014）",{"type":22,"tag":98,"props":555,"children":556},{},[557,562,567,572],{"type":22,"tag":116,"props":558,"children":559},{},[560],{"type":27,"value":561},"减掉的体重里去脂组织占比",{"type":22,"tag":116,"props":563,"children":564},{},[565],{"type":27,"value":566},"14.6%（10.5 到 18.7）",{"type":22,"tag":116,"props":568,"children":569},{},[570],{"type":27,"value":571},"30.2%（26.4 到 33.9）",{"type":22,"tag":116,"props":573,"children":574},{},[575],{"type":27,"value":576},"−15.6 个百分点",{"type":22,"tag":98,"props":578,"children":579},{},[580,585,590,595],{"type":22,"tag":116,"props":581,"children":582},{},[583],{"type":27,"value":584},"减掉的体重里脂肪占比",{"type":22,"tag":116,"props":586,"children":587},{},[588],{"type":27,"value":589},"85.3%（81.2 到 89.5）",{"type":22,"tag":116,"props":591,"children":592},{},[593],{"type":27,"value":594},"69.5%（65.7 到 73.3）",{"type":22,"tag":116,"props":596,"children":597},{},[598],{"type":27,"value":599},"+15.8 个百分点",{"type":22,"tag":98,"props":601,"children":602},{},[603,608,613,618],{"type":22,"tag":116,"props":604,"children":605},{},[606],{"type":27,"value":607},"脂肪减少",{"type":22,"tag":116,"props":609,"children":610},{},[611],{"type":27,"value":612},"8.5 kg（7.4 到 9.6）",{"type":22,"tag":116,"props":614,"children":615},{},[616],{"type":27,"value":617},"8.0 kg（7.0 到 9.0）",{"type":22,"tag":116,"props":619,"children":620},{},[621],{"type":27,"value":622},"0.5 kg，基本等于没有",{"type":22,"tag":98,"props":624,"children":625},{},[626,631,636,641],{"type":22,"tag":116,"props":627,"children":628},{},[629],{"type":27,"value":630},"体重减少",{"type":22,"tag":116,"props":632,"children":633},{},[634],{"type":27,"value":635},"11.2 kg（9.6 到 12.7），−12.3%",{"type":22,"tag":116,"props":637,"children":638},{},[639],{"type":27,"value":640},"12.5 kg（11.1 到 13.9），−13.4%",{"type":22,"tag":116,"props":642,"children":643},{},[644,646],{"type":27,"value":645},"1.3 kg，",{"type":22,"tag":34,"props":647,"children":648},{},[649],{"type":27,"value":650},"多的那边是安慰剂",{"type":22,"tag":23,"props":652,"children":653},{},[654],{"type":27,"value":655},"就第一行本身而言，这是个实打实的发现：半年里多保住 1.9 kg 去脂组织，换成公司用的英制单位是 4.2 磅（80% CI 2.55 到 5.84）。安全性没什么特别的，不过时间也短：apitegromab 组 51 人中 39 人（76%）出现不良事件，安慰剂组 51 人中 36 人（71%），多是胃肠道的轻度反应，两组各有 1 例严重事件（2%），没有死亡。这里没有把骨折列为发现，但这项试验只做了 24 周，而骨折信号来自一项 52 周的试验和一个多年的延长期，观察的又是本来骨头就脆的人。",{"type":22,"tag":71,"props":657,"children":659},{"id":658},"embraze-没能测到什么",[660],{"type":27,"value":661},"EMBRAZE 没能测到什么",{"type":22,"tag":23,"props":663,"children":664},{},[665,667,672],{"type":27,"value":666},"力量和体能——真正会被本人感觉到的那两件事——是测了的：优势手的握力，以及一个人能从椅子上站起来几次。但它们只是",{"type":22,"tag":34,"props":668,"children":669},{},[670],{"type":27,"value":671},"探索性",{"type":27,"value":673},"终点，一项试验里最低的那一档，既没有相应的检验效能，也没有多重比较的校正，因此定不了任何事。论文原话是这么写的：",{"type":22,"tag":675,"props":676,"children":677},"blockquote",{},[678],{"type":22,"tag":23,"props":679,"children":680},{},[681],{"type":27,"value":682},"在第 24 周和第 32 周的其他探索性终点上，apitegromab 与安慰剂在心血管代谢参数和体能相对基线的变化上，分别都没有观察到值得注意的差异。",{"type":22,"tag":23,"props":684,"children":685},{},[686],{"type":27,"value":687},"以及这句话背后的数字，来自论文的扩展数据：",{"type":22,"tag":90,"props":689,"children":690},{},[691,711],{"type":22,"tag":94,"props":692,"children":693},{},[694],{"type":22,"tag":98,"props":695,"children":696},{},[697,702,706],{"type":22,"tag":102,"props":698,"children":699},{},[700],{"type":27,"value":701},"相对基线的变化",{"type":22,"tag":102,"props":703,"children":704},{},[705],{"type":27,"value":38},{"type":22,"tag":102,"props":707,"children":708},{},[709],{"type":27,"value":710},"安慰剂",{"type":22,"tag":109,"props":712,"children":713},{},[714,732,750,768],{"type":22,"tag":98,"props":715,"children":716},{},[717,722,727],{"type":22,"tag":116,"props":718,"children":719},{},[720],{"type":27,"value":721},"坐立测试次数，第 24 周",{"type":22,"tag":116,"props":723,"children":724},{},[725],{"type":27,"value":726},"2.4（SD 3.0），n = 43",{"type":22,"tag":116,"props":728,"children":729},{},[730],{"type":27,"value":731},"2.2（SD 2.5），n = 44",{"type":22,"tag":98,"props":733,"children":734},{},[735,740,745],{"type":22,"tag":116,"props":736,"children":737},{},[738],{"type":27,"value":739},"坐立测试次数，第 32 周",{"type":22,"tag":116,"props":741,"children":742},{},[743],{"type":27,"value":744},"3.3（SD 3.8），n = 42",{"type":22,"tag":116,"props":746,"children":747},{},[748],{"type":27,"value":749},"2.2（SD 1.7），n = 43",{"type":22,"tag":98,"props":751,"children":752},{},[753,758,763],{"type":22,"tag":116,"props":754,"children":755},{},[756],{"type":27,"value":757},"握力，kg，第 24 周",{"type":22,"tag":116,"props":759,"children":760},{},[761],{"type":27,"value":762},"0.9（SD 6.9），n = 43",{"type":22,"tag":116,"props":764,"children":765},{},[766],{"type":27,"value":767},"−0.3（SD 8.5），n = 44",{"type":22,"tag":98,"props":769,"children":770},{},[771,776,781],{"type":22,"tag":116,"props":772,"children":773},{},[774],{"type":27,"value":775},"握力，kg，第 32 周",{"type":22,"tag":116,"props":777,"children":778},{},[779],{"type":27,"value":780},"1.0（SD 7.6），n = 41",{"type":22,"tag":116,"props":782,"children":783},{},[784],{"type":27,"value":785},"0.1（SD 6.9），n = 43",{"type":22,"tag":23,"props":787,"children":788},{},[789,791],{"type":27,"value":790},"要看的不是中间那个数，而是离散程度：每一行的标准差都是两组差距的好几倍，个体之间的差异把治疗之间的差异整个淹没了。报告里没有给置信区间，也没有给 p 值，正因为这些是探索性的。这不是一项证明了力量没受影响的试验，而是一项压根没有被设计来回答这个问题的试验。老实的总结是：",{"type":22,"tag":34,"props":792,"children":793},{},[794],{"type":27,"value":795},"一项体成分的测量改善了，而测量「人能做到什么」的那些指标没有。",{"type":22,"tag":71,"props":797,"children":799},{"id":798},"去脂体重不等于肌肉",[800],{"type":27,"value":798},{"type":22,"tag":23,"props":802,"children":803},{},[804,806,811],{"type":27,"value":805},"DXA（双能 X 线吸收测定法）扫描的原理，是看身体对两种能量的 X 射线吸收得有多不一样，据此把全身分成几类，其中一类就叫",{"type":22,"tag":34,"props":807,"children":808},{},[809],{"type":27,"value":810},"去脂体重",{"type":27,"value":812},"：所有既不是脂肪、也不是骨矿物质的东西。肌肉在里面，但肝、肾、肠道和结缔组织也在里面，水也在里面——而在快速减重的过程中，水是到处跑的。去脂体重是一个组织的量，不是一种能力。作者自己在论文里写了：「DEXA 扫描难以区分去脂体重内部的各个成分，准确性还会受到水合状态的影响。」",{"type":22,"tag":23,"props":814,"children":815},{},[816,818,824],{"type":27,"value":817},"这并不等于说 1.9 kg 没有意义。它的意思是：这条推论链有三环——去脂体重更多，所以肌肉更多，所以力量更大、功能更好——而目前只有第一环被证明了。这一类药物在这条推论链上恰好有个前车之鉴：bimagrumab 是一款针对受体的抗体，在更早的一项随机试验里增加了老年人的大腿肌肉体积，而同一篇论文写的是「肌肉力量没有变化」。那段历史我们在 ",{"type":22,"tag":54,"props":819,"children":821},{"href":820},"\u002Fpeptides\u002Ffollistatin-344",[822],{"type":27,"value":823},"follistatin-344 的页面",{"type":27,"value":825},"里讲过。",{"type":22,"tag":71,"props":827,"children":829},{"id":828},"标题里不会写的三个发现",[830],{"type":27,"value":828},{"type":22,"tag":23,"props":832,"children":833},{},[834,839,841,846],{"type":22,"tag":34,"props":835,"children":836},{},[837],{"type":27,"value":838},"脂肪减得一样多。",{"type":27,"value":840}," 按公斤算是 8.5 对 8.0——半公斤，比它自己的标准误 0.86 还小。被引用得最多的那组对照——加了抗体是「85% 脂肪、15% 去脂」，不加是「70 比 30」——完全是",{"type":22,"tag":34,"props":842,"children":843},{},[844],{"type":27,"value":845},"比例",{"type":27,"value":847},"上的差别；而两边的比例之所以不一样，是因为分母里去脂的那一份缩小了，不是因为掉下来的脂肪更多了。",{"type":22,"tag":23,"props":849,"children":850},{},[851,856],{"type":22,"tag":34,"props":852,"children":853},{},[854],{"type":27,"value":855},"加了这一味，体重反而减得少一点。",{"type":27,"value":857}," 11.2 kg 对 12.5 kg，差 1.3 kg，多的那边是单用替尔泊肽。作者说两组减重相似，这话公道，但这肯定不是网上流传的那种「减得更多，而且减得更好」的故事。",{"type":22,"tag":23,"props":859,"children":860},{},[861,866],{"type":22,"tag":34,"props":862,"children":863},{},[864],{"type":27,"value":865},"优势里的大部分，停药八周就没了。",{"type":27,"value":867}," 到第 32 周，也就是两种治疗都停掉八周之后，去脂体重的差距只剩 0.9 kg（80% CI 0.3 到 1.5；名义 p = 0.0480）——两个月里一半以上的差距消失了。剩下的那点会不会保住，没人知道：试验到这里就结束了。",{"type":22,"tag":71,"props":869,"children":871},{"id":870},"保住-549-肌肉这个标题拆开来看",[872],{"type":27,"value":873},"「保住 54.9% 肌肉」这个标题，拆开来看",{"type":22,"tag":23,"props":875,"children":876},{},[877,879,884,886,891,893],{"type":27,"value":878},"在报道里最卖力的那个数字是 ",{"type":22,"tag":34,"props":880,"children":881},{},[882],{"type":27,"value":883},"54.9%",{"type":27,"value":885},"，而它是个相对数：加了这一味之后，去脂体重的损失比不加时少了 54.9%——1.6 kg 而不是 3.5 kg。它不是说谁身上 54.9% 的肌肉被保住了，也不是体成分里的某个占比。真正告诉你效应有多大的是绝对数：在总共减掉约 12 kg 的人身上，",{"type":22,"tag":34,"props":887,"children":888},{},[889],{"type":27,"value":890},"24 周多保住 1.9 kg",{"type":27,"value":892},"。相对数字并不骗人，它只是惯例，但听上去大得多。每次都得追问一句：",{"type":22,"tag":216,"props":894,"children":895},{},[896],{"type":27,"value":897},"这是谁的百分之多少，换算成公斤又是几公斤？",{"type":22,"tag":71,"props":899,"children":901},{"id":900},"一个罕见病的批准不意味着什么",[902],{"type":27,"value":900},{"type":22,"tag":23,"props":904,"children":905},{},[906],{"type":27,"value":907},"同一个分子，两种完全不同的处境。在脊髓性肌萎缩症这边，有被审评过的获益风险权衡，有具法律效力的说明书，有上市后的随访义务，还有一项 188 人的三期试验，终点是一个功能量表，对象是不治疗就会持续失去运动能力的人群。在减重保去脂体重这边，只有一项在大体健康的成年人里做的二期概念验证研究，终点是一台机器给出的一个数字。9% 对 2% 的骨折率，放在一个会一点点夺走生活自理能力的病面前，和放在一个美容目标面前，分量完全不同。",{"type":22,"tag":23,"props":909,"children":910},{},[911,913,918],{"type":27,"value":912},"2026 年 9 月 21 日在 ClinicalTrials.gov 上检索，apitegromab 名下有七项登记的研究：六项在 SMA 或面肩肱型肌营养不良里，一项在肥胖里，就是已完成的 EMBRAZE。",{"type":22,"tag":34,"props":914,"children":915},{},[916],{"type":27,"value":917},"肥胖适应症没有三期",{"type":27,"value":919},"——没有登记，没有在任何地方提交，也没有宣布过；Scholar Rock 自己在这个方向上的下一步还停在临床前。今天读到「有药能对付减重掉肌肉」的人，读到的其实是一项 87 人、半年的可行性研究，而它的体能测量什么也没测出来。",{"type":22,"tag":71,"props":921,"children":923},{"id":922},"这一类里的其他药说的是同一件事",[924],{"type":27,"value":925},"这一类里的其他药，说的是同一件事",{"type":22,"tag":90,"props":927,"children":928},{},[929,950],{"type":22,"tag":94,"props":930,"children":931},{},[932],{"type":22,"tag":98,"props":933,"children":934},{},[935,940,945],{"type":22,"tag":102,"props":936,"children":937},{},[938],{"type":27,"value":939},"项目",{"type":22,"tag":102,"props":941,"children":942},{},[943],{"type":27,"value":944},"体成分",{"type":22,"tag":102,"props":946,"children":947},{},[948],{"type":27,"value":949},"功能上有结果吗？",{"type":22,"tag":109,"props":951,"children":952},{},[953,976,999],{"type":22,"tag":98,"props":954,"children":955},{},[956,966,971],{"type":22,"tag":116,"props":957,"children":958},{},[959,964],{"type":22,"tag":34,"props":960,"children":961},{},[962],{"type":27,"value":963},"Apitegromab",{"type":27,"value":965},"（Scholar Rock），EMBRAZE，二期已完成——针对肌抑素前体的抗体",{"type":22,"tag":116,"props":967,"children":968},{},[969],{"type":27,"value":970},"去脂体重减少 1.6 对 3.5 kg；去脂在减掉的体重里占 14.6% 对 30.2%",{"type":22,"tag":116,"props":972,"children":973},{},[974],{"type":27,"value":975},"没有——探索性终点，没有值得注意的差异",{"type":22,"tag":98,"props":977,"children":978},{},[979,989,994],{"type":22,"tag":116,"props":980,"children":981},{},[982,987],{"type":22,"tag":34,"props":983,"children":984},{},[985],{"type":27,"value":986},"Trevogrumab",{"type":27,"value":988},"（Regeneron），COURAGE，二期进行中——针对成熟肌抑素的抗体，部分与抗激活素 A 抗体联用",{"type":22,"tag":116,"props":990,"children":991},{},[992],{"type":27,"value":993},"单用司美格鲁肽时，减掉的体重里 33.0% 是去脂组织（−3.3 kg）；两种联用分别是 −1.5 kg（16.8%）和 −1.9 kg（18.1%）；三联是 −0.9 kg（7.4%）",{"type":22,"tag":116,"props":995,"children":996},{},[997],{"type":27,"value":998},"主要来源里没有报告",{"type":22,"tag":98,"props":1000,"children":1001},{},[1002,1012,1017],{"type":22,"tag":116,"props":1003,"children":1004},{},[1005,1010],{"type":22,"tag":34,"props":1006,"children":1007},{},[1008],{"type":27,"value":1009},"Bimagrumab",{"type":27,"value":1011},"（Versanis\u002F礼来），BELIEVE，二期——针对激活素 II 型受体的抗体，作用在受体这一层，覆盖面更宽",{"type":22,"tag":116,"props":1013,"children":1014},{},[1015],{"type":27,"value":1016},"第 72 周，联用组全身去脂体重 −2.9%，单用司美格鲁肽组 −7.4%；体重 −22.1% 对 −15.7%；脂肪 −45.7% 对 −27.8%",{"type":22,"tag":116,"props":1018,"children":1019},{},[1020],{"type":27,"value":1021},"从已发表的终点看不出来",{"type":22,"tag":23,"props":1023,"children":1024},{},[1025,1027,1032],{"type":27,"value":1026},"三个各自独立的项目，一个一致的结果：阻断肌抑素，或者阻断它传信号用的那个受体，",{"type":22,"tag":34,"props":1028,"children":1029},{},[1030],{"type":27,"value":1031},"确实把减掉的体重往脂肪那一侧挪了，而且挪的幅度测得出来",{"type":27,"value":1033},"；但到今天为止，没有一个项目发表过在力量或身体能力上占优的证据。",{"type":22,"tag":71,"props":1035,"children":1037},{"id":1036},"兴奋剂一份名单上有另一份上没有",[1038],{"type":27,"value":1039},"兴奋剂：一份名单上有，另一份上没有",{"type":22,"tag":23,"props":1041,"children":1042},{},[1043,1045,1050,1052,1057,1059,1065],{"type":27,"value":1044},"按 2026 年世界反兴奋剂机构（WADA）禁用清单的 ",{"type":22,"tag":34,"props":1046,"children":1047},{},[1048],{"type":27,"value":1049},"S4.3",{"type":27,"value":1051}," 条，apitegromab 在赛内赛外一律禁用；它在那一条里被直接点名，而且排在最前面：「中和肌抑素或其前体的抗体（例如 apitegromab、domagrozumab、landogrozumab、stamulumab）」。S4.3 里的物质属于",{"type":22,"tag":34,"props":1053,"children":1054},{},[1055],{"type":27,"value":1056},"非特定物质",{"type":27,"value":1058},"，是两类里更严的那一类。更完整的图景见我们的",{"type":22,"tag":54,"props":1060,"children":1062},{"href":1061},"\u002Fpeptides-banned-in-sport",[1063],{"type":27,"value":1064},"运动中被禁的肽",{"type":27,"value":1066},"一文。",{"type":22,"tag":23,"props":1068,"children":1069},{},[1070,1072,1077],{"type":27,"value":1071},"德国刑法这边正好反过来：《反兴奋剂法》的附表",{"type":22,"tag":34,"props":1073,"children":1074},{},[1075],{"type":27,"value":1076},"没有",{"type":27,"value":1078},"点 apitegromab 的名。在「改变肌抑素功能的物质」项下，它只列了卵泡抑素及其衍生物和 stamulumab，兜底条款也只覆盖这两者的盐、酯、异构体、络合物和衍生物。这是在陈述一份名单上写了什么，不是法律意见，而且只是此刻的快照：附表会定期修订，而 WADA 已经列名，未来被写进去的可能性不小。德国这个空白，对体育上的禁令没有任何影响。",{"type":22,"tag":71,"props":1080,"children":1082},{"id":1081},"它不是灰市肽也当不成灰市肽",[1083],{"type":27,"value":1084},"它不是灰市肽，也当不成灰市肽",{"type":22,"tag":23,"props":1086,"children":1087},{},[1088],{"type":27,"value":1089},"apitegromab 和论坛上挂着「肌抑素抑制剂」名头的那一堆东西，就是在这里彻底分道扬镳的。它是一个约 150 kDa 的单克隆抗体，靠哺乳动物细胞培养生产；而化学合成肽——那些被当作科研肽卖的小瓶背后的工艺——顶多做到 5 到 10 kDa 上下。网上挂出「apitegromab」即用型产品的卖家，既没有生产过也没有检测过这个分子；合法存在的是实验室试剂，卖给做细胞和动物实验的人，标签上明写着它不是临床用药。配制药房也做不出来，而 FDA 2026 年发给肽类卖家的警告信里，一个肌抑素抗体都没提到——任何地方的警告信、安全警示或进口警报，都没有点过 apitegromab 的名。",{"type":22,"tag":23,"props":1091,"children":1092},{},[1093,1095,1100,1102,1108,1110,1116],{"type":27,"value":1094},"它和",{"type":22,"tag":54,"props":1096,"children":1097},{"href":820},[1098],{"type":27,"value":1099},"卵泡抑素",{"type":27,"value":1101},"的区别也不是表面文章，尽管这两个名字最常被放在一起说：卵泡抑素是人体自己的结合蛋白，除了肌抑素之外，它还会把激活素 A、GDF-11 以及好几种促进成骨的生长因子一起捆住，也就是说它恰恰不具选择性。法律层面的框架，我们在",{"type":22,"tag":54,"props":1103,"children":1105},{"href":1104},"\u002Fare-peptides-legal",[1106],{"type":27,"value":1107},"肽是否合法",{"type":27,"value":1109},"里讲过；",{"type":22,"tag":54,"props":1111,"children":1113},{"href":1112},"\u002Fwhat-are-peptides",[1114],{"type":27,"value":1115},"什么是肽",{"type":27,"value":1117},"则是从零讲起——顺带一提，apitegromab 并不算肽。",{"type":22,"tag":71,"props":1119,"children":1121},{"id":1120},"小结",[1122],{"type":27,"value":1120},{"type":22,"tag":23,"props":1124,"children":1125},{},[1126],{"type":27,"value":1127},"2026 年 9 月 11 日 apitegromab 以 ISEMBYLD 获批，这确实是头一回：二十年的失败之后，一款阻断肌抑素的药通过了监管机构，适应症是脊髓性肌萎缩症，依据是一个改善了 2.2 分的功能量表。它对减重什么也没说。",{"type":22,"tag":23,"props":1129,"children":1130},{},[1131],{"type":27,"value":1132},"减重这边只有一项二期研究：随机 102 人，分析 87 人，24 周，80% 置信区间。它测到的是 DXA 扫描上多保住 1.9 kg 去脂体重——而这台机器并不能把这个差值拆成肌肉、器官组织还是水。按公斤算脂肪减得一样多，加了这一味体重反而减得少一点，停药八周后差距缩到 0.9 kg。力量和从椅子上站起来的能力只是顺带测了测，没有值得注意的差异。没有三期，任何地方都没有申请。",{"type":22,"tag":23,"props":1134,"children":1135},{},[1136],{"type":27,"value":1137},"扫描上的数字动了。人自己能感觉到的东西会不会跟着动，得由下一项试验来回答——如果还有下一项的话。",{"type":22,"tag":71,"props":1139,"children":1141},{"id":1140},"来源",[1142],{"type":27,"value":1140},{"type":22,"tag":1144,"props":1145,"children":1146},"ul",{},[1147,1163,1176,1188,1202,1216,1228,1240,1254,1266,1280,1293,1306,1320,1332,1346,1360],{"type":22,"tag":1148,"props":1149,"children":1150},"li",{},[1151,1153,1161],{"type":27,"value":1152},"FDA, ",{"type":22,"tag":54,"props":1154,"children":1158},{"href":1155,"rel":1156},"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2026\u002F761463Orig1s000lbl.pdf",[1157],"nofollow",[1159],{"type":27,"value":1160},"Prescribing Information ISEMBYLD (apitegromab-mstn)",{"type":27,"value":1162},", BLA 761463",{"type":22,"tag":1148,"props":1164,"children":1165},{},[1166,1167,1174],{"type":27,"value":1152},{"type":22,"tag":54,"props":1168,"children":1171},{"href":1169,"rel":1170},"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Fappletter\u002F2026\u002F761463Orig1s000ltr.pdf",[1157],[1172],{"type":27,"value":1173},"BLA Approval Letter, BLA 761463",{"type":27,"value":1175},", 11 September 2026",{"type":22,"tag":1148,"props":1177,"children":1178},{},[1179,1180,1187],{"type":27,"value":1152},{"type":22,"tag":54,"props":1181,"children":1184},{"href":1182,"rel":1183},"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fnews-events-human-drugs\u002Ffda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy",[1157],[1185],{"type":27,"value":1186},"FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy",{"type":27,"value":1175},{"type":22,"tag":1148,"props":1189,"children":1190},{},[1191,1193,1200],{"type":27,"value":1192},"EMA, ",{"type":22,"tag":54,"props":1194,"children":1197},{"href":1195,"rel":1196},"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fisembyld",[1157],[1198],{"type":27,"value":1199},"Isembyld — EPAR overview, application withdrawn 13 August 2026",{"type":27,"value":1201}," (procedure EMEA\u002FH\u002FC\u002F005909)",{"type":22,"tag":1148,"props":1203,"children":1204},{},[1205,1207,1214],{"type":27,"value":1206},"Pratley RE, Denham D, Trivedi R, et al., Nature Medicine 2026;32(7):2673–2678, ",{"type":22,"tag":54,"props":1208,"children":1211},{"href":1209,"rel":1210},"https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fs41591-026-04440-4",[1157],[1212],{"type":27,"value":1213},"Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial",{"type":27,"value":1215}," (EMBRAZE, NCT06445075)",{"type":22,"tag":1148,"props":1217,"children":1218},{},[1219,1221],{"type":27,"value":1220},"Crawford TO, Servais L, Mercuri E, et al., The Lancet Neurology 2025;24(9):727–739, ",{"type":22,"tag":54,"props":1222,"children":1225},{"href":1223,"rel":1224},"https:\u002F\u002Fdoi.org\u002F10.1016\u002FS1474-4422(25)00225-X",[1157],[1226],{"type":27,"value":1227},"Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE)",{"type":22,"tag":1148,"props":1229,"children":1230},{},[1231,1233],{"type":27,"value":1232},"Crawford TO, Darras BT, Day JW, et al., Neurology 2024;102(5):e209151, ",{"type":22,"tag":54,"props":1234,"children":1237},{"href":1235,"rel":1236},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC11067700\u002F",[1157],[1238],{"type":27,"value":1239},"Safety and Efficacy of Apitegromab in SMA Types 2 and 3: the phase 2 TOPAZ study",{"type":22,"tag":1148,"props":1241,"children":1242},{},[1243,1245,1252],{"type":27,"value":1244},"Heymsfield SB, Aronne LJ, et al., Nature Medicine 2026, ",{"type":22,"tag":54,"props":1246,"children":1249},{"href":1247,"rel":1248},"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41591-026-04204-0",[1157],[1250],{"type":27,"value":1251},"Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial",{"type":27,"value":1253}," (BELIEVE, NCT05616013)",{"type":22,"tag":1148,"props":1255,"children":1256},{},[1257,1259],{"type":27,"value":1258},"Look M, et al., Diabetes Obesity and Metabolism 2025, ",{"type":22,"tag":54,"props":1260,"children":1263},{"href":1261,"rel":1262},"https:\u002F\u002Fdoi.org\u002F10.1111\u002Fdom.16275",[1157],[1264],{"type":27,"value":1265},"Body composition changes during weight reduction with tirzepatide in SURMOUNT-1",{"type":22,"tag":1148,"props":1267,"children":1268},{},[1269,1271,1278],{"type":27,"value":1270},"Scholar Rock, SEC Form 8-K Exhibit 99.1, ",{"type":22,"tag":54,"props":1272,"children":1275},{"href":1273,"rel":1274},"https:\u002F\u002Fwww.sec.gov\u002FArchives\u002Fedgar\u002Fdata\u002F1727196\u002F000110465926107273\u002Ftm2625362d1_ex99-1.htm",[1157],[1276],{"type":27,"value":1277},"Scholar Rock Announces FDA Approval of ISEMBYLD (apitegromab-mstn)",{"type":27,"value":1279},", 14 September 2026",{"type":22,"tag":1148,"props":1281,"children":1282},{},[1283,1284,1291],{"type":27,"value":1270},{"type":22,"tag":54,"props":1285,"children":1288},{"href":1286,"rel":1287},"https:\u002F\u002Fwww.sec.gov\u002FArchives\u002Fedgar\u002Fdata\u002F1727196\u002F000110465925092317\u002Ftm2526733d1_ex99-1.htm",[1157],[1289],{"type":27,"value":1290},"FDA Issues Complete Response Letter for Apitegromab, solely related to observations at a third-party fill-finish facility",{"type":27,"value":1292},", 23 September 2025",{"type":22,"tag":1148,"props":1294,"children":1295},{},[1296,1297,1304],{"type":27,"value":1270},{"type":22,"tag":54,"props":1298,"children":1301},{"href":1299,"rel":1300},"https:\u002F\u002Fwww.sec.gov\u002FArchives\u002Fedgar\u002Fdata\u002F1727196\u002F000155837025008711\u002Fsrrk-20250618xex99d1.htm",[1157],[1302],{"type":27,"value":1303},"Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results",{"type":27,"value":1305},", 18 June 2025",{"type":22,"tag":1148,"props":1307,"children":1308},{},[1309,1311,1318],{"type":27,"value":1310},"ClinicalTrials.gov, ",{"type":22,"tag":54,"props":1312,"children":1315},{"href":1313,"rel":1314},"https:\u002F\u002Fclinicaltrials.gov\u002Fsearch?intr=apitegromab",[1157],[1316],{"type":27,"value":1317},"all registered apitegromab studies",{"type":27,"value":1319},", queried 21 September 2026",{"type":22,"tag":1148,"props":1321,"children":1322},{},[1323,1325],{"type":27,"value":1324},"Regeneron, press releases of 2 June 2025 and 17 September 2025, ",{"type":22,"tag":54,"props":1326,"children":1329},{"href":1327,"rel":1328},"https:\u002F\u002Finvestor.regeneron.com\u002Fnews-releases",[1157],[1330],{"type":27,"value":1331},"full 26-week COURAGE results for trevogrumab with semaglutide",{"type":22,"tag":1148,"props":1333,"children":1334},{},[1335,1337,1344],{"type":27,"value":1336},"World Anti-Doping Agency, ",{"type":22,"tag":54,"props":1338,"children":1341},{"href":1339,"rel":1340},"https:\u002F\u002Fwww.wada-ama.org\u002Fen\u002Fprohibited-list",[1157],[1342],{"type":27,"value":1343},"The 2026 Prohibited List",{"type":27,"value":1345},", section S4.3",{"type":22,"tag":1148,"props":1347,"children":1348},{},[1349,1351,1358],{"type":27,"value":1350},"Annex to section 2(3) of the German Anti-Doping Act, ",{"type":22,"tag":54,"props":1352,"children":1355},{"href":1353,"rel":1354},"https:\u002F\u002Fwww.gesetze-im-internet.de\u002Fantidopg\u002F",[1157],[1356],{"type":27,"value":1357},"BGBl. 2023 I No. 67",{"type":27,"value":1359},", part III item 3",{"type":22,"tag":1148,"props":1361,"children":1362},{},[1363,1364,1371],{"type":27,"value":1152},{"type":22,"tag":54,"props":1365,"children":1368},{"href":1366,"rel":1367},"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnuscience-peptides-llc-733652-08242026",[1157],[1369],{"type":27,"value":1370},"Warning Letter to NuScience Peptides LLC, 733652",{"type":27,"value":1372},", 24 August 2026",{"title":7,"searchDepth":1374,"depth":1374,"links":1375},2,[1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389],{"id":73,"depth":1374,"text":76},{"id":199,"depth":1374,"text":202},{"id":336,"depth":1374,"text":339},{"id":473,"depth":1374,"text":476},{"id":658,"depth":1374,"text":661},{"id":798,"depth":1374,"text":798},{"id":828,"depth":1374,"text":828},{"id":870,"depth":1374,"text":873},{"id":900,"depth":1374,"text":900},{"id":922,"depth":1374,"text":925},{"id":1036,"depth":1374,"text":1039},{"id":1081,"depth":1374,"text":1084},{"id":1120,"depth":1374,"text":1120},{"id":1140,"depth":1374,"text":1140},"markdown","content:blog:zh:apitegromab-isembyld-glp1-muscle.md","content","blog\u002Fzh\u002Fapitegromab-isembyld-glp1-muscle.md","blog\u002Fzh\u002Fapitegromab-isembyld-glp1-muscle","md"]